Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Columbia University Irving Medical Center, New York, New York University of Pennsylvania - Abramson Caner Center, Philadelphia, Pennsylvania